Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V (Open-House-Modell)

Under uniform contractual terms and a standardized access procedure, all suitable and interested pharmaceutical companies or consortia of pharmaceutical companies are offered the opportunity to conclude or join a discount agreement pursuant to Section 130a Paragraph 8 of the German Social Code, Book V (SGB V), for the aforementioned active ingredients. Interested pharmaceutical companies can request the participation documents and the contract from the contact address (am-vertragsteam@he.aok.de). A prerequisite for concluding a contract is that the interested pharmaceutical company submits the requested participation documents fully completed, stamped, and signed in the original. A contract will be concluded with every pharmaceutical company that meets the participation requirements. Exclusivity is not guaranteed. This publication does not constitute a public procurement procedure within the meaning of Directive 2014/24/EU or procurement law. To ensure the greatest possible transparency regarding the intended contract conclusions, the publication is appearing in the Supplement to the Official Journal of the European Union. In the absence of a suitable publication form, the contract notice is used. The resulting terminology, such as the procedure designation "open procedure," is solely due to the use of this publication form and platform. It has no further meaning, in particular, it does not imply subjection to procurement regulations, unless legally mandatory.